Pharmafile Logo
Pharmafocus logo
Advanced Search

HUTCHMED

Showing 4 posts of 4 posts found.

HUTCHMED completes enrolment in phase 3 trial for lung cancer

August 21, 2025
Research and Development HUTCHMED, Oncology, clinical trial, lung cancer, non-small cell lung cancer

HUTCHMED has completed patient enrolment for the SANOVO phase 3 clinical trial, investigating the use of ORPATHYS (savolitinib) in combination …

News

NDA in China receives priority review status for lung cancer treatment

January 3, 2025
Research and Development China, China National Medical products Administration, HUTCHMED, NDA, Oncology, epidermal growth factor receptor, non-small cell lung cancer, priority review

HUTCHMED have announced that the China National Medical Products Administration (NMPA) have granted a priority review for a new drug …

News
blood-1813410_960_720

Hutchmed announces phase 3 trial met primary endpoint for primary immune thrombocytopenia treatment

August 21, 2023
Research and Development HUTCHMED, Haematology, clinical trial, sovleplenib, thrombocytopenia

Hutchmed has announced that its phase 3 trial ESLIM-01 trial assessing the use of sovleplenib has met its primary endpoint …

News

Takeda and HUTCHMED’s cancer drug shown to prolong overall survival

June 16, 2023
Research and Development HUTCHMED, Oncology, Takeda, colorectal cancer

Clinical trial data from a study into the metastatic colorectal cancer (CRC) drug fruquintinib, which is being developed by Japanese …

News
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026